SMS Lifesciences India Limited
Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, a… Read more
Market Cap & Net Worth: SMS Lifesciences India Limited (SMSLIFE)
SMS Lifesciences India Limited (NSE:SMSLIFE) has a market capitalization of $44.98 Million (₹3.90 Billion) as of March 18, 2026. Listed on the NSE stock exchange, this India-based company holds position #28693 globally and #1550 in its home market, demonstrating a -3.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SMS Lifesciences India Limited's stock price ₹1288.50 by its total outstanding shares 3023287 (3.02 Million).
SMS Lifesciences India Limited Market Cap History: 2017 to 2026
SMS Lifesciences India Limited's market capitalization history from 2017 to 2026. Data shows growth from $14.50 Million to $44.98 Million (30.20% CAGR).
SMS Lifesciences India Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SMS Lifesciences India Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.01x
SMS Lifesciences India Limited's market cap is 0.01 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.24x
SMS Lifesciences India Limited's market cap is 0.24 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $14.50 Million | $2.16 Billion | $126.47 Million | 0.01x | 0.11x |
| 2018 | $16.67 Million | $2.09 Billion | $65.01 Million | 0.01x | 0.26x |
| 2019 | $9.11 Million | $3.73 Billion | $178.47 Million | 0.00x | 0.05x |
| 2020 | $22.71 Million | $2.57 Billion | $101.83 Million | 0.01x | 0.22x |
| 2021 | $25.38 Million | $2.66 Billion | $135.57 Million | 0.01x | 0.19x |
| 2022 | $21.75 Million | $3.47 Billion | $253.22 Million | 0.01x | 0.09x |
| 2023 | $18.47 Million | $3.16 Billion | $114.63 Million | 0.01x | 0.16x |
| 2024 | $41.05 Million | $3.06 Billion | $90.93 Million | 0.01x | 0.45x |
| 2025 | $48.18 Million | $3.45 Billion | $201.09 Million | 0.01x | 0.24x |
Competitor Companies of SMSLIFE by Market Capitalization
Companies near SMS Lifesciences India Limited in the global market cap rankings as of March 18, 2026.
Key companies related to SMS Lifesciences India Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
SMS Lifesciences India Limited Historical Marketcap From 2017 to 2026
Between 2017 and today, SMS Lifesciences India Limited's market cap moved from $14.50 Million to $ 44.98 Million, with a yearly change of 30.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₹44.98 Million | -6.64% |
| 2025 | ₹48.18 Million | +17.36% |
| 2024 | ₹41.05 Million | +122.28% |
| 2023 | ₹18.47 Million | -15.09% |
| 2022 | ₹21.75 Million | -14.30% |
| 2021 | ₹25.38 Million | +11.77% |
| 2020 | ₹22.71 Million | +149.19% |
| 2019 | ₹9.11 Million | -45.35% |
| 2018 | ₹16.67 Million | +14.99% |
| 2017 | ₹14.50 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of SMS Lifesciences India Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $44.98 Million USD |
| MoneyControl | $44.98 Million USD |
| MarketWatch | $44.98 Million USD |
| marketcap.company | $44.98 Million USD |
| Reuters | $44.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.